Novozymes A/S B (NSISBc)

BATS Europe


	Symbol		Exchange		Currency
	NSISb		Copenhagen		DKK	Real-time
	NSISBc		BATS Europe		DKK	Delayed
	NVZMY		OTC Markets		USD	Delayed
	NVZMF		OTC Markets		USD	Delayed
	0Q4U		London		DKK	Real-time
	NZM2b		TradeGate		EUR	Delayed
	NZYMb		Vienna		EUR	Real-time

Currency in DKK

415.55

+0.35(+0.08%)

Closed04/12

Fair Value

Day's Range

411.00

415.55

52 wk Range

346.85

485.40

NSISBc Income Statement

Featured here, the Income Statement (earnings report) for Novozymes A/S B, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

14,374

14,012

14,951

17,553

17,899

Total Revenues Growth

-0.11%

-2.52%

+6.7%

+17.4%

+1.97%

Cost Of Revenues

6,387

6,159

6,313

7,963

8,177

Gross Profit

7,987

7,853

8,638

9,590

9,722

Gross Profit Growth

-3.78%

-1.68%

+10%

+11.02%

+1.38%

Gross Profit Margin %

55.57%

56.04%

57.78%

54.63%

54.32%

Other Operating Expenses, Total

4,399

4,190

4,744

5,109

5,259

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+6.18%	-4.75%	+13.22%	+7.69%	+2.94%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,966	1,905	1,982	1,986	2,017
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	2,459	2,299	2,828	3,198	3,325
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-26	-14	-66	-75	-83

Operating Income

3,588

3,663

3,894

4,481

4,463

Operating Income Growth

-13.71%

+2.09%

+6.31%

+15.07%

-0.4%

EBIT Margin %

24.96%

26.14%

26.05%

25.53%

24.93%

Net Interest Expenses

4

-53

-84

-84

-83

Net Interest Expenses Growth

+233.33%

-1,425%

-58.49%

0%

+1.19%

Interest Expense, Total

-86

-63

-102

-102

-173

Interest And Investment Income

90

10

18

18

90

Other Non Operating Expenses, Total

-239

-70

-28

-436

-135

EBT, Excl. Unusual Items

3,353

3,540

3,782

3,961

4,245

Gain (Loss) On Sale Of Assets

194

42

122

-

88

Other Unusual Items, Total

252

-32

20

195

135

EBT, Incl. Unusual Items

3,799

3,521

3,924

4,556

3,909

EBT, Incl. Unusual Items Growth

-3.48%

-7.32%

+11.45%

+16.11%

-14.2%

EBT, Incl. Unusual Items Margin

26.43%

25.13%

26.25%

25.96%

21.84%

Income Tax Expense

644

695

779

870

870

Net Income to Company

3,155

2,826

3,145

3,686

3,039

Minority Interest

-1

-1

1

-10

-15

Net Income

3,154

2,825

3,146

3,676

3,024

Net Income Growth

-2.23%

-10.43%

+11.36%

+16.85%

-17.74%

Net Income Margin %

21.94%

20.16%

21.04%

20.94%

16.89%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

3,154

2,825

3,146

3,676

3,024

Basic EPS - Continuing Operations

11.06

10.07

11.32

13.29

10.92

Basic EPS - Continuing Operations Growth

-0.41%

-8.94%

+12.37%

+17.39%

-17.85%

Diluted EPS - Continuing Operations

11.01

10.02

11.23

13.19

10.88

Diluted EPS - Continuing Operations Growth

-0.18%

-8.99%

+12.08%

+17.45%

-17.51%

Basic Weighted Average Shares Outstanding

285.11

280.43

277.92

276.64

277.04

Diluted Weighted Average Shares Outstanding

286.55

282.02

280.23

278.73

277.87

Dividend Per Share

5.25

5.25

5.5

6

6.2

Dividend Per Share Growth

+5%

0%

+4.76%

+9.09%

+3.33%

EBITDA

4,584

4,699

5,061

5,721

5,632

EBITDA Growth

-10.14%

+2.51%

+7.7%

+13.04%

-1.56%

EBITDA Margin %

31.89%

33.54%

33.85%

32.59%

31.47%

EBIT